[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602374":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":46,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"First Affiliated Hospital of Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"18F-Pentixafor PET\u002FCT in Hematologic Malignancies",null,"Each patient receive a single intravenous injection of 18F-Pentixafor 55 MBq\u002Fkg and undergo PET\u002FCT or PET\u002FMR scan after 60 min post-injection.",[13],"Drug: 18F-Pentixafor",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","18F-Pentixafor","Patients with hematological malignancies receive 55 MBq\u002Fkg of 18F-Pentixafor intravenously followed by PET\u002FCT or PET\u002FMR after 60min of injection.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Peipei Wang, MD","CONTACT","86 18511395988","wpp199411@163.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The First Affiliated Hospital of Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310003","China",{"type":35,"coordinates":36},"Point",[37,38],120.16142,30.29365,{"lat":38,"lon":37},[41,45],{"name":42,"role":23,"phone":43,"phoneExt":10,"email":44},"Xinhui Su, MD","86 13806071262","suxinhui@zju.edu.cn",{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100602374",false,"NCT07122674","18F-Pentixafor PET in Hematologic Malignancies","Prospective Clinical Study of 18F-Pentixafor PET Imaging in Hematologic Malignancies","Inclusion Criteria:\n\n1. Age of 18-80 years old, both sexes, with behavioral capacity;\n2. patients with suspected or confirmed hematological malignancies;\n3. 18F-FDG PET or other imaging examinations should be performed according to the treatment plan;\n4. For suspected patients, biopsy or needle biopsy is expected to obtain pathological results;\n5. Can provide informed consent, can understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. pregnant and lactating women;\n2. patients with fear or radiophobia, or with mental disorder or primary affective disorder;\n3. received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv;\n4. received investigational drugs or devices of uncertain efficacy or safety within 1 month;\n5. Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.","ALL","18 Years","80 Years",{"count":58,"type":59},100,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.",[63],"Hematological Malignancies","2025-08-07",{"date":66,"type":67},"2025-08-14","ACTUAL",{"date":69,"type":67},"2025-07-01",{"date":71,"type":59},"2029-12",{"name":5,"class":6},1]